TY  - CHAP
M1  - Book, Section
TI  - Peripheral Arterial Disease
A1  - Chow, Sheryl L.
A1  - Hoeben, Barbara J.
A2  - DiPiro, Joseph T.
A2  - Talbert, Robert L.
A2  - Yee, Gary C.
A2  - Matzke, Gary R.
A2  - Wells, Barbara G.
A2  - Posey, L. Michael
Y1  - 2017
N1  - 
T2  - Pharmacotherapy: A Pathophysiologic Approach, 10e
AB  - KEY  CONCEPTS  The  prevalence  of  peripheral  arterial  disease  (PAD)  is  dependent  on  age  and  the  presence  of  traditional  risk  factors  for  cardiovascular  disease  (CVD)  and  many  patients  are  undiagnosed;  undiagnosed  patients  have  substantial  risk  for  coronary  and  cerebrovascular  events.  The  clinical  presentation  of  PAD  is  variable  and  includes  a  range  of  symptoms.  The  two  most  common  characteristics  of  PAD  are  intermittent  claudication  (IC)  and  pain  at  rest  in  the  lower  extremities.  The  ankle-brachial  index  (ABI)  is  a  simple,  noninvasive,  quantitative  test  that  has  been  proven  to  be  a  highly  sensitive  and  specific  tool  in  the  diagnosis  of  PAD.  As  with  any  atherosclerotic  condition,  several  risk  factors  play  an  important  role  in  the  morbidity  and  mortality  of  peripheral  vascular  disease.  Many  of  these  risk  factors  are  modifiable  with  the  help  of  various  nonpharmacologic  and  pharmacologic  interventions.  Nonpharmacologic  interventions  such  as  smoking  cessation  and  walking  exercise  programs  have  the  ability  to  positively  impact  several  of  the  pathophysiologic  abnormalities  present  in  patients  with  PAD.1  Data  proving  that  antiplatelet  therapies  can  prevent  or  delay  the  progression  of  PAD  are  currently  unavailable.  However,  aspirin  therapy  has  repeatedly  been  proven  to  significantly  reduce  serious  vascular  events  in  these  “high-risk”  patients  and,  in  the  absence  of  contraindications,  is  highly  recommended.  After  appropriate  exercise  therapy  and  therapeutic  lifestyle  changes  (TLC)  have  been  implemented,  patients  who  continue  to  experience  severe  IC  may  benefit  from  additional  pharmacologic  therapy  with  cilostazol.  
SN  - 
PB  - McGraw-Hill Education
CY  - New York, NY
Y2  - 2024/04/20
UR  - accesspharmacy.mhmedical.com/content.aspx?aid=1145219364
ER  -